IP Library Granted Patent US 7,368,120
Granted Patent B2
US 7,368,120 · App. 11/046,936 · Granted May 6, 2008

Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol

Assignee: Sepracor Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,368,120
App. No.
11/046,936
Granted
May 6, 2008
Kind
B2
Abstract

A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, a low incidence of the development of tolerance and an increased duration of action, as compared to racemic formoterol.

Claims (11)

1. A method of reducing morbidity ascribable to high dose or long term use of β2 sympathomimetic bronchodilator drugs in an asthma patient, the method comprising administering to the asthma patient a therapeutically effective amount of (R,R)-formoterol, or a pharmaceutically acceptable salt thereof, the (R,R)-formoterol containing at least 90% by weight of (R,R)-formoterol and less than 10% by weight of (S,S)-formoterol.

2. The method of claim 1 , wherein the (R,R)-formoterol is administered by subcutaneous injection, intravenous infusion, inhalation, transdermal delivery or oral administration.

3. The method of claim 2 , wherein the (R,R)-formoterol or pharmaceutically acceptable salt thereof is administered together with a pharmaceutically acceptable carrier.

4. The method of claim 2 , wherein the (R,R)-formoterol is administered as the fumarate salt.

5. The method of claim 2 , wherein the (R,R)-formoterol is administered as the tartrate salt.

6. The method of claim 2 , wherein the (R,R)-formoterol is administered as the succinate salt.

7. The method of claim 2 , wherein the (R,R)-formoterol is administered by inhalation and the amount administered is about 1 μg to about 100 μg per day, in single or divided doses.

8. The method of claim 5 , wherein the amount administered is about 6 μg to about 25 μg per day, in single or divided doses.

9. The method of claim 6 , wherein the amount administered is about 12 μg to about 25 μg per day, in single or divided doses.

10. The method of claim 7 , wherein the amount is administered in from two to four divided doses.

11. The method of claim 2 , wherein the (R,R)-formoterol is administered orally and the amount administered is about 0.1 mg to about 1 mg per day.

Assignments (1)
CHANGE OF NAME Recorded Nov 18, 2010
From: SEPRACOR INC.
To: SUNOVION PHARMACEUTICALS INC.
Reel/Frame 025388/0806 →
Priority Claims (1)
GB 9107196.9 · Apr 5, 1991 · national
Continuity (12)
Continuation 1045712300 · Jun 9, 2003
Continuation 0992700800 · Aug 9, 2001
Continuation 0953520000 · Mar 27, 2000
Continuation 0913610900 · Aug 18, 1998
Continuation 0861338200 · Mar 7, 1996
Continuation In Part 0837351500 · Jan 12, 1995
Continuation In Part 0822231900 · Apr 4, 1994
Continuation 0792745800 · Aug 10, 1992
Continuation In Part 0838274400 · Feb 2, 1995
Continuation 0822379800 · Apr 6, 1994
Continuation 0786290700 · Apr 3, 1992
Related Publication 20050131072A1 · Jun 16, 2005